Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Clin Cancer Res. 2018 Feb 20;24(10):2408–2416. doi: 10.1158/1078-0432.CCR-17-3474

Figure 2. Efficacy of the ADT and VTP combination in the LNCaP-AR human prostate cancer model.

Figure 2

(A) Degarelix and VTP combination on tumor growth in athymic nude mice. Mice bearing LNCaP-AR tumors were randomly assigned to 4 cohorts: control (n=7), degarelix (n=9), VTP (n=8), and degarelix + VTP (n=9) and tumor size was measured weekly. The combination treatment suppressed tumor growth more efficiently (p<0.01 for combination vs degarelix, p<0.005 for combination vs VTP). (B) Combination of degarelix and VTP on tumor growth in SCID mice. Mice bearing LNCaP-AR tumors were randomly assigned to 4 cohorts: control (n=14), degarelix (n=14), VTP (n=17) and degarelix + VTP (n=16) and tumor size was measured weekly (p<0.0001, combination vs degarelix or VTP). Results were combined from two separate experiments. One dose of degarelix was given at 3 days prior to VTP.